Our study has several strengths, include the assessment of VEGF concentrations in a wide range of SSc subtypes (extent of fibrosis, video capillaroscopy patterns, and key clinical complications), the evaluation of the certainty of evidence for each endpoint, and the evaluation of specific study and patient characteristics associated with the effect size. This evidence concerns the gene VEGFA and systemic sclerosis.